title: Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma.
abstract: Hodgkin lymphoma (HL) and nasopharyngeal carcinoma (NPC) are characterized by their association with Epstein-Barr virus (EBV) and an abundant infiltrate of reactive lymphoid cells. The presence of this lymphoid stroma may influence the effect of anti-viral immunotherapy. The interferon-inducible chemokine IP-10 has anti-neoplastic effects in several model systems mediated by T-cells expressing the CXCR3 chemokine receptor. Using in situ hybridization, it is shown that IP-10 is expressed in neoplastic cells of HL and correlates both with the mixed cellularity histotype and with EBV infection. IP-10 expression was also detected in tumour cells of most NPCs as well as in EBV-negative squamous cell carcinomas of the tongue. Thus, in carcinomas, IP-10 expression showed no correlation with EBV infection. Numerous CXCR3-positive lymphocytes were detected in the lymphoid stroma of HL and NPC, raising the possibility of a Th1-predominant immune response in these cases. In view of the proposed anti-neoplastic functions of IP-10 and CXCR3-positive lymphocytes, these findings are unexpected and raise the possibility that endogenous IP-10 expression in the context of human tumours may not exert the anti-tumour effects ascribed to it by in vitro experiments.
authors.affiliation: Institute for Pathology, Friedrich-Alexander-University, Erlangen, Germany.
authors.forename: Martina
authors.initials: M
authors.lastname: Teichmann
authors.forename: Birgit
authors.initials: B
authors.lastname: Meyer
authors.forename: Andreas
authors.initials: A
authors.lastname: Beck
authors.forename: Gerald
authors.initials: G
authors.lastname: Niedobitek
mesh_terms: D000818:Animals; D002277:Carcinoma / Q000276:immunology* / Q000821:virology; D002294:Carcinoma, Squamous Cell / Q000276:immunology; D016022:Case-Control Studies; D045744:Cell Line, Tumor; D054357:Chemokine CXCL10; D019743:Chemokines, CXC / Q000032:analysis* / Q000276:immunology; D003110:Colonic Neoplasms / Q000276:immunology; D020031:Epstein-Barr Virus Infections / Q000276:immunology; D004854:Herpesvirus 4, Human; D006689:Hodgkin Disease / Q000276:immunology* / Q000821:virology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D017403:In Situ Hybridization; D051379:Mice; D008819:Mice, Nude; D009303:Nasopharyngeal Neoplasms / Q000276:immunology* / Q000821:virology; D009374:Neoplasms, Experimental; D012333:RNA, Messenger / Q000032:analysis; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine / Q000032:analysis / Q000235:genetics; D014062:Tongue Neoplasms / Q000276:immunology; D014763:Viral Matrix Proteins / Q000032:analysis / Q000235:genetics
chemical_list: C515187:CXCR3 protein, human; D054357:Chemokine CXCL10; D019743:Chemokines, CXC; C515188:Cxcr3 protein, mouse; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D012333:RNA, Messenger; D054367:Receptors, CXCR3; D019707:Receptors, Chemokine; D014763:Viral Matrix Proteins